Research Summary

I have worked within a diverse set of collaborations and with investigators across disciplines include pediatrics, nephrology, ophthalmology and HIV treatment. I have created and led short courses on survival analysis and causal inference. My statistical interests include clustering, competing risk/multiple outcomes, time-dependent covariates and informative censoring.

Research Funding

  • September 24, 2018 - August 31, 2022 - Statistical methods for clinical trials of novel PrEP agents , Principal Investigator . Sponsor: NIH/NIAIDS, Sponsor Award ID: R01AI143357
  • January 10, 2016 - December 31, 2017 - Comparison of Pharmacologic Markers of Exposure to HIV Pre-Exposure Prophylaxis , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R03AI122908
  • June 19, 2015 - May 31, 2017 - Chemoprophylaxis for HIV Prevention: Analysis of Bone and Metabolic Effects , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R03AI120819
  • April 1, 2001 - March 31, 2006 - FAILURE TIME METHODS FOR FAMILY DISEASE STUDIES , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01HL065411

Education

University of California, Berkeley, CA, BA, 1988, Statistics
University of Washington, Seattle, WA, PhD, 1993, Biostatistics
Harvard University, Boston, MA, Fellowship, 1995, Biostatistics

Honors & Awards

  • 1988
    W.W. Stout Fellowship, Graduate School, University of Washington
  • 1988 - 1990
    Graduate Fellowship Award, Graduate School, University of Washington
  • 1990 - 1993
    National Research Service Award, National Heart, Lung and Blood Institute
  • 1993
    School of Public Health Outstanding Student Citation for Biostatistics, Univ. of Washington
  • 2007
    TICR Award for Excellence in Teaching

Selected Publications

  1. Appa A, Marti XL, Baral S, Shoptaw S, Bazazi AR, Spinelli MA, Glidden D, Gandhi M, Coffin P The NOD (Naltrexone for Overdose Prevention) study protocol: a pilot randomized controlled trial of intramuscular naltrexone for opioid overdose prevention among people who use stimulants living with or at risk for HIV.  View on PubMed
  2. Scott HM, Roman J, Spinelli M, Bena J, Torres T, Glidden D, Buchbinder S Sexually transmitted infections after implementation of doxycycline postexposure prophylaxis.  View on PubMed
  3. Peluso MJ, Sandel DA, Deitchman AN, Kim SJ, Dalhuisen T, Tummala HP, Tibúrcio R, Zemelko L, Borgo GM, Singh SS, Schwartz K, Deswal M, Williams MC, Hoh R, Shimoda M, Narpala S, Serebryannyy L, Khalili M, Vendrame E, SenGupta D, Whitmore LS, Tisoncik-Go J, Gale M, Koup RA, Mullins JI, Felber BK, Pavlakis GN, Reeves JD, Petropoulos CJ, Glidden DV, Spitzer MH, Gama L, Caskey M, Nussenzweig MC, Chew KW, Henrich TJ, Yukl SA, Cohn LB, Deeks SG, Rutishauser RL Correlates of HIV-1 control after combination immunotherapy.  View on PubMed
  4. Greenland JR, Perch M, Halloran K, Levine DJ, Morrell ED, Reed A, Shaver CM, Singer JP, Sweet SC, Vos R, Aryal S, Avdimiretz N, Burrows F, Calabrese D, Calabrese F, Campos S, Combs M, de Perrot M, Dellgren G, Diamond JM, Egan T, Ging P, Glidden DV, Goddard M, Jyothula S, Keller M, Kulkarni H, Kwakkel-van Erp JM, Lama V, Marczin N, Martinu T, Neely ML, Palmer SM, Patterson CM, Pavlisko EN, Pham C, Sanchez M, Schultz HHL, Schwerk N, Shah U, Shashaty M, Singer L, Smith P, Snyder LD, Solomon M, Verleden S, Verplancke V, Zeevi A, Todd JL Considerations for Endpoints in Lung Transplant Clinical Trials: An ISHLT Consensus Statement.  View on PubMed
  5. Gebreegziabher EA, Ouattara M, Bountogo M, Coulibaly B, Boudo V, Ouedraogo T, Lebas E, Hu H, Glidden DV, Arnold BF, Lietman TM, Sié A, Oldenburg CE Trends in uncomplicated and severe malaria following seasonal malaria chemoprevention administration in Nouna, Burkina Faso: a quasi-experimental pre-post study.  View on PubMed
  6. Dunn DT, Stirrup OT, Glidden DV Sample size estimation for the averted events ratio.  View on PubMed
  7. Molina MF, Eucker SA, Rising KL, Kean ER, Rafique Z, Mesbah H, Glidden DV, Arreguin MI, Alvarez C, Rodriguez RM COVID-19 Booster Vaccine Messaging in Emergency Departments: A Cluster Randomized Clinical Trial.  View on PubMed
  8. Gebreegziabher EA, Ouattara M, Bountogo M, Coulibaly B, Boudo V, Ouedraogo T, Lebas E, Hu H, O'Brien KS, Hsiang MS, Glidden DV, Arnold BF, Lietman TM, Sié A, Oldenburg CE The role of seasonal malaria chemoprevention in the effect of azithromycin on child mortality: A secondary analysis of the CHAT cluster randomized clinical trial.  View on PubMed
  9. Ghanooni D, Heise MJ, Sassaman K, Glidden DV, Martinson T, Mahuvakar S, Duncan DT, Horvath KJ, Hirshfield S, Williams R, Johnson MO, Grov C, Gandhi M, Carrico AW, Spinelli M Suboptimal ART adherence, undetectable urine tenofovir, and higher C-reactive protein values.  View on PubMed
  10. Bicki AC, Nguyen SM, Rojas GA, Glidden DV, Grimes B, Ku E Reduced Access to Second Kidney Transplantation Among Adolescent Girls.  View on PubMed
  11. Nadig N, Bhimraj A, Cawcutt K, Chiotos K, Dzierba AL, Kim AY, Martin GS, Pearson JC, Shumaker AH, Baden LR, Bedimo R, Cheng VC, Chew KW, Daar ES, Glidden DV, Hardy EJ, Johnson S, Li JZ, MacBrayne C, Nakamura MM, Riley L, Shafer RW, Shoham S, Tebas P, Tien PC, Loveless J, Falck-Ytter Y, Morgan RL, Gandhi RT 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Abatacept.  View on PubMed
  12. Mugwanya KK, Saina M, Mugo NR, MaWhinney S, Morrow M, Schaafsma TT, Donnell D, Glidden DV, Ngure K, Brown CE, Rechkina EA, Chohan BH, Wu L, Hill E, Koome E, Akelo N, Mbaire S, Morrison SA, Kibatha M, Njeru I, Muriithi M, Coppinger C, Bushman L, Baeten JM, Anderson PL, Women Benchmark Study Team Adherence thresholds for emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis against HIV acquisition in cisgender women: A randomized directly observed dosing study.  View on PubMed
  13. Nadig N, Bhimraj A, Cawcutt K, Chiotos K, Dzierba AL, Kim AY, Martin GS, Pearson JC, Shumaker AH, Baden LR, Bedimo R, Cheng VC, Chew KW, Daar ES, Glidden DV, Hardy EJ, Johnson S, Li JZ, MacBrayne C, Nakamura MM, Riley L, Shafer RW, Shoham S, Tebas P, Tien PC, Loveless J, Falck-Ytter Y, Morgan RL, Gandhi RT 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Infliximab.  View on PubMed
  14. Bhimraj A, Falck-Ytter Y, Baden LR, Bedimo R, Cawcutt K, Cheng VC, Chew KW, Chiotos K, Daar ES, Dzierba AL, Glidden DV, Hardy EJ, Johnson S, Kim AY, Li JZ, MacBrayne C, Martin GS, Nadig N, Nakamura MM, Pearson JC, Riley L, Shafer RW, Shoham S, Shumaker AH, Tebas P, Tien PC, Loveless J, Morgan RL, Gandhi RT 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critica  View on PubMed
  15. Byakwaga H, Semeere A, Laker-Oketta M, Busakhala N, Freeman E, Rotich E, Wenger M, Kadama-Makanga P, Kisuya J, Semakadde M, Mwine B, Kasozi C, Mwebesa B, Maurer T, Glidden DV, Wools-Kaloustian K, Kambugu A, Martin J Survival Following Diagnosis of HIV-Associated Kaposi Sarcoma Among Adults in East Africa in the "Treat-All" Era.  View on PubMed
  16. Gebreegziabher EA, Sié A, Ouattara M, Bountogo M, Coulibaly B, Boudo V, Ouedraogo T, Lebas E, Hu H, Ante-Testard PA, Gregorich SE, O'Brien KS, Hsiang MS, Glidden DV, Arnold BF, Lietman TM, Oldenburg CE Exploring Heterogeneity in Treatment Effects: The Impact and Interaction of Asset-Based Wealth and Mass Azithromycin Distribution on Child Mortality.  View on PubMed
  17. van Zyl GU, Decloedt E, Jennings L, Kellermann T, Motha K, van Schalkwyk M, Schreuder C, Coetzee N, Glidden DV, Orrell C, Gandhi M A real-time urine tenofovir assay improves drug adherence among people with HIV with prior virologic failure in a randomized controlled trial.  View on PubMed
  18. Koenig LR, Raymond EG, Upadhyay UD, Frye LJ, Kaneshiro B, Boraas CM, Oldenburg CE, Glidden DV Effectiveness and safety of medication abortion with vs. without screening ultrasonography or pelvic exam.  View on PubMed
  19. Beavers C, Pau AK, Glidden D, Hyle E, Kuriakose S, Martin SS, McComsey G, Thompson M, Virani S, Baker JV Statin Therapy as Primary Prevention for Persons With HIV: A Synopsis of Recommendations From the U.S. Department of Health and Human Services Antiretroviral Treatment Guidelines Panel.  View on PubMed
  20. Nadig N, Bhimraj A, Cawcutt K, Chiotos K, Dzierba AL, Kim AY, Martin GS, Pearson JC, Shumaker AH, Baden LR, Bedimo R, Cheng VC, Chew KW, Daar ES, Glidden DV, Hardy EJ, Johnson S, Li JZ, MacBrayne C, Nakamura MM, Riley L, Shafer RW, Shoham S, Tebas P, Tien PC, Loveless J, Falck-Ytter Y, Morgan RL, Gandhi RT 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab.  View on PubMed

Go to UCSF Profiles, powered by CTSI